Ray of hope for advanced breast cancer patients: US approves new oral drug Inluriyo

A significant step towards the fight against breast cancer has come into existence. The US Food and Drug Administration has approved a first in class oral therapy for those battling against one most common cancers in the world, breast cancer. The approval announced in a press release by the US FDA is being hailed as a breakthrough in the fight against breast cancer, as the new drug has shown to reduce the risk of disease progression or death by approximately 33% in patients whose tumors are resistant to standard hormonal. therapies.

Why Inluriyo brings a new hope

Existing treatments such as aromatase inhibitors or fulvestrant injections have improved survival, however, many breast cancer patients develop resistance linked to ESR1 mutations. These mutations make cancer cells less responsive to standard hormonal therapies. The new drug imlunestrant or the given brand name Inluriyo by Eli Lilly and Company directly addresses this problem. This means, for patients whose tumors have become resistant to hormonal therapies, Inluriyo can directly attack the cells that fuel tumor growth by blocking and degrading the estrogen receptors. By targeting this mechanism and cutting off the cancer cells’ primary source of stimulation, Inluriyo offers a precision therapy approach.


Unlike injection, Inliuriyo is in the form of pills and offers patients a convenient treatment option. It belongs to a class of drugs called Selective Estrogen Receptor Degraders (SERDs). Inluriyo prevents the tumor cells from using estrogen to survive and multiply.

What is ESR1-mutated advanced breast cancer

ESR1-mutated advanced breast cancer is a type of estrogen receptor (ER) positive breast cancer, where cancer cells have acquired mutations in the ESR1 gene. The ESR1 gene produces estrogen receptors that help the tumor grow by responding to the hormone estrogen. When mutations occur, cancer cells often become resistant to standard hormone therapies, making the treatment more challenging. Inluriyo works by blocking and degrading estrogen receptors, effectively cutting off the tumor’s main growth signal. Clinical trials have shown that Inluriyo can reduce the risk of disease progression or death by about 33–38% in patients with ESR1-mutated tumors.

Key takeaways

• FDA-approved the first oral therapy for ESR1-mutated advanced breast cancer called Inluriyo.
• Inluriyo targets hormone resistant tumors by blocking and degrading estrogen receptors.
• Clinical trials showed a 33–38% reduction in risk of disease progression.
• Inluriyo is an oral drug that offers a convenient alternative to injectable therapies.

According to the press release issued by FDA, the recommended dose of Inluriyo is once a day 400 mg orally on an empty stomach at least 2 hours before food, or 1 hour after food. A report published by Webmd highlights that the oral drug Inluriyo can harm the unborn child during pregnancy, and breastfeeding is also not recommended during the treatment.